A b s t r a c t
PS6K, a putative oncogene mapped to chromosome 17q23, encodes a serine/threonine kinase, which phosphorylates ribosomal subunit 6 and is part of the insulin receptor signal transduction pathway involved in the regulation
Specific genetic alterations are considered critical to the initiation and progression of various neoplasms. Gene amplification is a common mechanism involved in cellular transformation. By November 1997, approximately 20 genes had been reported to be amplified in a broad spectrum of tumors. 1 As a relatively new genomic screening tool, comparative genomic hybridization (CGH) is a useful technique for identifying novel regions of amplification in cancer. 1 Until recently, no amplifications had been described in primary human meningiomas. However, CGH has suggested that chromosome 17q22-23 amplification or gain occurs in up to 42% of high-grade (atypical and anaplastic) meningiomas. [2] [3] [4] PS6K encodes a serine/threonine protein kinase designated as P70 S6K or P85 S6K , depending on the molecular weight of the isoforms. This kinase is a member of the insulin-like growth factor-PI3 kinase-mammalian target of rapamycin signal transduction pathway. It functions immediately downstream of the mammalian target of rapamycin and represents a major branching point in the pathway. 5 By phosphorylating its major substrate, the ribosomal subunit 6 protein, PS6K has a pivotal role in the regulation of messenger RNA translation, protein synthesis, cell cycle progression, and cell size. Disruption of PS6K in mouse 6 and Drosophila 7 models results in marked reduction in adult body size. Recently, PS6K has been localized to chromosome region 17q23 and found to be amplified in a subset of breast cancer, another hormonally driven neoplasm. 8 Given its known cellular functions and its localization within the region of reported amplification, PS6K represents a logical candidate gene being targeted for overexpression in malignant meningiomas.
To explore the potential role of PS6K in the tumorigenesis and malignant progression of meningiomas, we assessed PS6K gene dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization (FISH). We found high-level PS6K gene amplifications in a subset ( 
Materials and Methods

Patient and Tumor Population
We selected 119 clinicopathologically well-characterized meningiomas from the surgical pathology files at Mayo Clinic and Washington University School of Medicine for study. The clinical and pathologic features for most of the cases have been reported. 9, 10 Histologic grading was performed using our newly formulated scheme, 10 which differs only slightly from the most recently modified version published by the WHO. 11 Atypical meningiomas (WHO grade II) were defined by high mitotic index (4 or more per 10 high-power fields or 2.5/mm 2 ), brain invasion, or the presence of at least 3 selected variables (sheeting architecture, macronucleoli, hypercellularity, small cells). Anaplastic meningiomas (WHO grade III) were characterized by excessive proliferation (20 or more mitoses per 10 high-power fields or 12.5/mm 2 ) or loss of meningothelial differentiation at the light microscopic level (ie, carcinoma, sarcoma, or melanoma-like appearance).
In Situ Hybridization
Unstained, 5-µm-thick sections were cut from archival formalin-fixed paraffin-embedded blocks and mounted on Superfrost Plus precleaned glass slides (Fisher Scientific, Pittsburgh, PA). The sections were deparaffinized with Hemo-D (Sigma, St Louis, MO) and washed 3 times with isopropanol, followed by running tap water and distilled water. Target retrieval was done by steaming in a rice cooker for 20 minutes in a 10-mmol/L concentration of citrate buffer, pH 6.0. After cooling to room temperature, the slides were subjected to protease digestion with 40 mg/mL of pepsin in distilled water at 37°C for 20 to 40 minutes. After washing with distilled water and 2× sodium chloride and sodium citrate buffer (SSC), the slides were air dried.
Paired DNA probes consisted of a previously reported digoxigenin-labeled bacterial artificial chromosome (BAC) probe localized to the PS6K region (RPCI-II Human BAC Library, Research Genetics, Huntsville, AL) 8 and CEN 17, a chromosome 17 centromeric probe labeled with SpectrumGreen (Vysis, Downers Grove, IL). Both probes were codiluted 1:50 in DenHyb buffer (Insitus, Albuquerque, NM).
Ten microliters of the hybridization mix was applied to each slide, cover glasses were applied to the slides, and the slides were sealed with rubber cement. Denaturing was achieved by incubating the slides at 90°C for 13 minutes on a metal tray. The tray then was transferred to a Styrofoam box (Insitus) for slow cooling for 30 minutes or longer. The slides, along with the metal tray, were incubated at 37°C overnight in a humidified oven. After hybridization, the cover glasses and rubber cement were removed, and the slides were washed for 5 minutes with 50% formamide in 1× SSC followed by a second wash with 2× SSC and a third wash with phosphate-buffered saline (PBS), 5 minutes each.
Detection of digoxigenin-labeled probe was performed by blocking the slides with blocking buffer (1% bovine serum albumin, 0.2% powdered skim milk, 0.3% Triton X-100 in PBS), followed by incubation in a humidified chamber with 1:500 diluted CY3 conjugated antidigoxigenin antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) in blocking buffer for 1 hour at room temperature. After 3 washes with PBS, the slides were air dried and counterstained with DAPI/Antifade (Insitus). Fluorescent signals were enumerated under an Olympus BX60 fluorescent microscope with appropriate filters (Olympus, Melville, NY). Nuclei with innumerable small and/or large globular red signals were considered to harbor high-level PS6K amplification ❚Image 1❚. Low-level amplifications were defined by PS6K/CEN17 ratios of 2 to 4.
Differential Polymerase Chain Reaction
Formalin-fixed paraffin-embedded tissue was cut onto glass slides from the anaplastic meningioma demonstrating amplification by FISH in the greatest fraction of cells (25%; Image 1) ❚Image 2❚. Slides were deparaffinized in Histoclear (National Diagnostics, Atlanta, GA) for 10 minutes before DNA extraction with the QIAamp Tissue Extraction kit (QIAGEN, Arlington Heights, IL). Samples were eluted in a 100-µL volume of water. Primer pairs used were as follows: PS6K-1561S (5'-CCC ATG ATC TCC AAA CGG CC-3') and PS6K-1680AS (5'-TGT TTC ACC TTG CAG GAT GC-3') or PS6K-1511S (5'-CAC TTC CAA TAC GAC AGC CG-3') and PS6K-1680AS in combination with primers for amplification of part of the cystic fibrosis gene (CF), the sequences for which have been described previously. 12 One microliter of each DNA sample was used in a 50-µL amplification reaction containing the following: 10 pmol of sense and antisense primer for both PS6K and CF; 200-µmol/L deoxynucleoside triphosphate, 1.5-mmol/L magnesium chloride, 50-mmol/L potassium chloride, and 10-mmol/L tris(hydroxymethyl)aminomethane hydrochloride (pH8.3) concentrations; 0.001% gelatin, 5% dimethyl sulfoxide, and 1.25 U of Amplitaq Gold (Perkin-Elmer, Foster City, CA). Reactions were carried out in a Perkin-Elmer 9600 using the following conditions: 95°C hold for 9 minutes followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute followed by a 10-minute hold at 72°C. Samples were then electrophoresed through a 3% agarose gel and stained with ethidium bromide. Relative band intensities were quantitated by the Gel Documentation System (BioRad, Hercules, CA).
Results
We analyzed 119 archival paraffin-embedded meningiomas with dual-color FISH. Twenty-five cases with weak PS6K signals precluding accurate interpretation were excluded from further analysis. The FISH data for the remaining 94 cases are summarized in ❚Table 1❚. PS6K amplification was not detected in 37 cases of benign or 35 cases of atypical meningioma. In contrast, 3 (14%) of 22 cases of anaplastic meningiomas showed high-level amplification (Image 1, Table 1 ). Therefore, PS6K amplification was restricted to a subset of anaplastic meningiomas. Other known clinical, pathologic, and genetic variables for these 3 cases are summarized in ❚Table 2❚. These cases did not differ in any obvious way from anaplastic meningiomas without amplification with the possible exception of a lack of associated 1p deletions by FISH in the 2 informative cases ( Table  2 ). In comparison, 14 (88%) of 16 informative anaplastic meningiomas without PS6K amplification demonstrated 1p deletion using probes to 1p32 and 1p36 (data not shown). Differential polymerase chain reaction confirmed the PS6K amplification in one of the anaplastic meningiomas (Image 2). The 2.5-fold increase was consistent with the fact that FISH demonstrated high-level amplification in only 25% of cells, and, therefore, a considerable fraction of nonamplified tumor DNA also was examined.
Discussion
We report high-level PS6K gene amplification in a small subset of anaplastic meningiomas. To our knowledge, this represents the first reported example of a specific gene amplification in human meningiomas. PS6K localizes to chromosome 17q23, a region found to be gained or amplified in meningiomas by recent CGH studies. [2] [3] [4] 14 The development of molecular cytogenetic techniques, such as CGH and reverse chromosome painting, 15 has allowed detection of gene dosage changes in entire tumor genomes and, thus, is useful for obtaining a gross survey of overall genetic abnormalities.
Thus far, the results of CGH studies on meningiomas have varied greatly. In an analysis of 59 meningiomas, Weber et al 2 found high-level amplification of chromosome 17q in 0 of 19 benign, 1 of 21 atypical, and 8 of 19 anaplastic meningiomas. In another CGH analysis of 18 meningiomas lacking 22q loss of heterozygosity, Khan et al 3 found a single case showing 17q amplification. Metzger et al 4 reported 17q gain in 21% of malignant meningiomas but did not comment on any high-level amplifications. Ozaki et al 14 reported no amplifications of 17q from 20 patients (13 benign, 4 atypical, and 3 anaplastic meningiomas). It is unclear whether these discrepancies reflect differences in patient populations or technical interpretive variability associated with performing CGH.
Compared with other common central nervous system neoplasms such as gliomas, little is known about the molecular and cytogenetic abnormalities in meningiomas. Loss of genetic material of chromosome 22q or inactivation of the NF2 (neurofibromatosis 2) gene at this location has been demonstrated in 30% to 80% of sporadic meningiomas, regardless of tumor grade. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Recently, Perry et al 13 found that the NF2 gene product merlin was lost in 74% of meningiomas, and DAL-1, a newly discovered family member of merlin, was similarly lost in 76% meningiomas. Loss of either merlin or DAL-1 was almost universal (92%). Other cytogenetic abnormalities involving chromosomes 1p, 3p, 6q, 9q, 10q, and 14q also have been reported. [2] [3] [4] 14 Specific genes such as PTEN, p16, p53, and p73 have been essentially excluded for mutations or allelic loss. [27] [28] [29] [30] [31] [32] [33] [34] Therefore, much remains unknown concerning the genetic basis of meningioma tumorigenesis and progression. In the present study, we assessed a specific candidate gene, PS6K, within the chromosome 17q23 region, implicated by CGH studies. We found high-level gene amplification in a small subset of anaplastic meningiomas but not in benign or atypical meningiomas. Our results, along with those of others, strongly suggest that PS6K and/or other genes in the 17q amplicon are involved in malignant progression of a subset of meningiomas. Our 3 cases with demonstrable amplification did not seem to differ clinicopathologically in any obvious way from other anaplastic meningiomas without amplification, with the possible exception of chromosome 1p status. Neither of our 2 amplified cases informative for 1p status demonstrated losses by FISH, whereas 16 (89%) of 18 anaplastic meningiomas without amplification harbored deletions (Table 2 ; unpublished data). These 1p data are taken from a currently ongoing study to further characterize our meningiomas genetically. Unfortunately, the numbers are too small to determine whether PS6K amplification and 1p deletion might be mutually exclusive events that might somehow be biologically linked. In any case, FISH analysis for PS6K dosage is a simple, fast technique to screen for 17q23 amplification. It can be applied to routinely prepared, archival, formalin-fixed, paraffin-embedded meningiomas with an 80% success rate in our hands. Additional probes and technical refinements likely would improve this capture rate.
Several recent studies have suggested that PS6K probably has an important role in tumorigenesis. For example, the PS6K pathway is constitutively active in human pancreatic cancer tissue and cell lines. 35 Attachment and spreading of cells on extracellular matrix proteins triggers integrin-dependent activation of PS6K. 36 Furthermore, PS6K-mediated protein synthesis was found to be a critical step for vascular endothelial cell cycle progression in response to growth factors. 37 Thus, it seems that PS6K is important not only in growth factor signal transduction but also in angiogenesis and interaction with the extracellular matrix, both essential for successful tumor growth.
If PS6K amplification is indeed important for meningioma progression, one must explain why it is found only in a small subset of tumors. Gene redundancy and functional compensation provide one plausible explanation. In other words, important genes are thought to be duplicated occasionally during evolution, providing a genetic "backup" for critical biochemical pathways. This is one potential explanation for the lack of any reported effect on viability or fertility in PS6K knockout mice, even though the PS6K-deficient mice are smaller than wild-type. Furthermore, ribosome subunit 6 is normally phosphorylated in response to mitogen stimulation in these knockout mice. 6 These observations further supported the gene redundancy hypothesis and led to the discovery of a PS6K homolog designated PS6K2/PS6Kbeta. 6, [38] [39] [40] [41] Currently, the chromosomal localization of PS6K2/PS6Kbeta is unknown. However, it will be important to determine whether PS6K2/PS6K2beta might be amplified similarly in anaplastic meningiomas, especially those showing no evidence of PS6K amplification.
Alternatively, other genes within the 17q23 amplicon may turn out to have greater significance than PS6K, potentially accounting for the higher fraction of malignant meningiomas with gene amplification reported in one CGH study. 2 In the present study, we used a BAC probe that contains 133.4 kilobases of DNA, including one known expressed sequence tag (WI-17810) in addition to the PS6K gene. The function of this second potential gene and any possible tumorigenic relevance is unknown. Detailed mapping studies of this 17q23 region are under way in the laboratory of one of us (C.D.J.) and hopefully will clarify some of these issues. Gene chip microarray technology also could provide potential insight in terms of overexpression patterns.
High-level PS6K gene amplification characterizes a small subset of anaplastic meningiomas, suggesting a potential role in malignant progression of meningiomas. Our results represent the first example of specific gene amplification in human meningiomas, although additional studies are required to determine whether PS6K is the most relevant candidate gene in the 17q23 amplicon.
